Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

New guidelines have been developed for the treatment of schizophrenia through a collaborative effort of international experts ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

New guidelines have been developed ... likely to choose to stick with treatment." "There are promising new treatments on the horizon," Professor Siskind. "GLP-1 receptor agonists for example ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic ...

A new study published in the Journal of American Medical Association showed that glucagon-like peptide-1 receptor agonists ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The number of people without diabetes taking a GLP-1 drug more than tripled between ... risk of death by sticking to diet and exercise guidelines recommended by the American Cancer Society ...